Cadonilimab (Not yet branded)
Immunotherapy
Description
Cadonilimab (AK104) is a bispecific antibody immunotherapy agent that simultaneously targets both PD-1 and CTLA-4 immune checkpoint pathways in a single molecule. In colorectal cancer treatment, it is being used in combination with chemotherapy regimens like mFOLFOXIRI and bevacizumab for both locally advanced and metastatic disease. The drug shows activity across different molecular subtypes including microsatellite stable (MSS), microsatellite instability-high (MSI-H), and BRAF-mutated colorectal cancers.
Mechanism of Action
Cadonilimab functions as a bispecific immune checkpoint inhibitor that blocks both PD-1 and CTLA-4 receptors on T cells, effectively removing dual brakes on the immune system. By simultaneously inhibiting these two key checkpoint pathways, it aims to enhance T cell activation and tumor immune response more effectively than single-agent checkpoint inhibitors.
Molecular Targets
Side Effects
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.
Clinical Trials
Quick Info
| Brand Name | Not yet branded |
| Category | Immunotherapy |
 Status | Experimental |
 EMA Status | Experimental |
 Spain Access | Not available |
| Administration | IV |
| Clinical Trials | 19 |
Related Medications
Medical Disclaimer
This information is for educational purposes only and should not replace professional medical advice. Always consult your healthcare team before making treatment decisions.